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Glioblastomas (GBM) may receive inadequate radiation dose 
coverage, specially the nonenhanced hypercellular 
component, using post-Gd T1 weighted and T2 FLAIR images 
for radiation target definition. A mixture of edema, micro-
necrosis, tumor cells and normal tissue in a single image 
voxel result in an unpredictable value on diffusion images 
using a conventional b-value of 1000 s/mm2 or less. This 
study aimed to develop a technique to identify the 
hypercellular components of GBM by using high b-value 
diffusion weighted imaging (DWI) to suppress fluid, edema, 
micro-necrosis and even normal tissue to an extent.  The 
hypercellular volume (HCV) of the tumor was evaluated for 
radiation dose coverage and prediction of progression-free 
survival (PFS). 
Forty patients with newly diagnosed GBM underwent 
chemoradiotherapy post-resection/biopsy. The target 
definition was based upon conventional MRI and RT 
treatment planning followed standard guidelines.  Pre-RT 
DWI was acquired with b-values of 0, 1000, and 3000 s/mm2. 
A HCV was defined on the DWI with b=3000 s/mm2 by a 
threshold obtained from normal tissue.  The nonenhanced 
HCV was delineated by comparing to the Gd-enhanced gross 
tumor volume (GTV-Gd) on T1-weighted images. Radiation 
coverage of the HCV was evaluated by the 95% prescribed 
dose-volume (95%PDV) of the planned dose distribution.  
Association between HCV and PFS or other clinical covariates 
were assessed using univariate proportional hazards 
regression models. 
For the first 21 patients with a minimum follow-up of 18 
months, the HCVs varied 0.58-67 cc (median: 9.8cc), 7 times 
smaller than the FLAIR-defined CTV.  The non-enhanced HCV 
was 0.15-60 cc (median: 2.5cc). However, incomplete dose 
coverage of the HCV was seen in 14 patients, in whom 6 had 
at least 1-cc HCV missed by the 95%PDV (range: 1.01-25.4cc). 
Of the 21 patients, 15 had progressed, 5 patients earlier 
within 6 months post-RT, and 10 patients >6 months post-RT.  
HCV and nonenhanced HCV were significant negative 
predictors for PFS (p<0.002 and p<0.01, respectively). The 
component of the HCV that was not covered by the 95%PDV 
was a significant negative predictor for PFS (p<0.05).  The 
proportion of pre-RT HCVs that overlapped with recurrent 
Gd-enhanced tumor volume was 78% (range: 65-89%) for the 5 
earlier progressors, and 53% (range: 0-85%) for the later 
progressors.   
The HCV identified by high b-value DWI most likely 
represents an aggressive component of the tumor, and 
analysis of the data from the whole cohort is in progress.  
Pathological validation is on-going.  Post-Gd T1 weighted 
images (a qualitative measure of vascular leakage) and T2 
FLAIR images (influenced by edema) are not adequate for 
radiation target definition of GBM. Selectively boosting the 
HCV component of GBM will be tested in a prospective 
clinical trial. 
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Fig 1. Diffusion weighted images with b=3000. Yellow: HCV; 
Red: post-Gd GTV; Pink: 95%PDV. 
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Early assessment of therapeutic response in NSCLC is of 
major importance to individualize treatment, ultimately 
improving outcome. Radiomics comprises the extraction of a 
large set of quantitative descriptors from medical images (1). 
We hypothesised that a Radiomics analysis of variation of 
metabolic uptake patterns of repeated FDG-PET (Figure 1) 
allows early response assessment and validated our findings 
in external datasets. 
A prospective dataset of 54 stage IIIa-IV NSCLC patients 
referred for radical (chemo)radiotherapy was used for 
prediction model development. The validation datasets 
included 32 stage IIb-IIIb (details in (2)) and 26 stage IIa-IIIb 
(details in (3)) NSCLC patients. FDG-PET scans were acquired 
before and during second week of radiotherapy. Radiomics 
analysis included descriptors of shape and size, first order 
statistics, textural information [run-length grey level (RLGL), 
grey level co-occurrence (GLCM) and grey level size zone 
matrices (GLSZM)] and intensity volume histograms (IVH). For 
analysis, solely features with a high intraclass correlation 
(ICC) on both test-retest and inter-observer stability analysis 
were kept (4). Cox Proportional Hazard Regression was 
performed for overall survival assessment, with the relative 
percentage variation of each feature between subsequent 
scans as continuous covariates: 
 
